Manufacturer
PHARMANIAGA LIFESCIENCE SDN. BHD.
Contents
Indication
Acute pulmonary oedema and Oedema associated with heart failure.
Instruction
Acute pulmonary oedema
Adult: 40 mg via slow inj over 1-2 minutes. If no adequate response within 1 hour, a further 80 mg may be given via slow IV inj over 1-2 minutes.
Oedema associated with heart failure
Adult: 20-50 mg via IM or slow IV inj, may increase by increments of 20 mg 2 hrly. Doses >50 mg must be given via slow IV infusion. Max: 1,500 mg daily.
Child: 0.5-1.5 mg/kg daily. Max: 20 mg daily.
Drug interaction
May increase nephrotoxicity of cephalosporins (e.g. cefalotin), NSAIDs. May increase ototoxicity of aminoglycoside, ethacrynic acid, other ototoxic drugs. Reduced serum level w/ aliskiren. May increase hypotensive effect of ACE inhibitors or angiotensin II receptor antagonists. Increased risk of hyperkalaemia w/ K-sparing diuretics. Increased risk of cardiotoxicity w/ cardiac glycosides, antihistamines. May reduce serum level of lithium. May antagonise hypoglycaemic effect of antidiabetics. Increased hypotensive effect w/ MAOIs. Increased hyponatraemia w/ carbamazepine. Reduced natriuretic and hypotensive effect w/ indometacin. Diminished diuretic effect w/ salicylates.
Malaysia
